|
|
|
| Prediction of neoantigens and their application in cancer treatment |
| Bao Jin a, Ying-Yi Wang b, Shun-Da Du a,∗ |
a Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and PUMC, #1 Shuai-Fu-Yuan,
Dongcheng District, Beijing 100730, China
b Department of Medical Oncology, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and PUMC, #1 Shuai-Fu-Yuan,
Dongcheng District, Beijing 100730, China
∗ Corresponding author.
E-mail address: dushd@pumch.cn (S.-D. Du). |
|
|
|
|
Abstract Tumor antigens can be divided into tumor-associated antigens and tumor-specific antigens according to their specificity. Tumorassociated antigens are not unique to tumor cells, and can also be synthesized in small amounts by normal cells. Tumor-specific antigens, also called neoantigens, are formed by peptides that are entirely absent from the normal human genome [1]. Neoantigens are antigenic epitope peptides of the major histocompatibility complex (MHC) located on the surface of malignant cells. They are derived from unique mutations in tumor cells, such as non-synonymous point mutations, indels, gene fusions, or frame shift mutations. The body mounts an immune response against tumors based on the presence of tumor antigens. Neoantigens are produced by mutations in tumor cells and are tumor-specific; therefore, immunotherapy targeting neoantigens does not undergo central and peripheral immune tolerance and has fewer side effects. Thus, neoantigens have many potential applications in immunotherapy of tumors, especially in hepatobiliary and pancreatic cancer.
|
|
|
|
|
|
|
|
|
2018, Vol. 17 
